Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C07K16/10

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2025/140539ULTRAPOTENT BROARDLY NEUTRALIZING ANTIBODIES AGAINST SARS-COV-2 VARIANTS AND METHODS OF USE THEREOF
WO 03.07.2025
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/CN2024/143146 Applicant THE UNIVERSITY OF HONG KONG Inventor CHEN, Zhiwei
Provided is in the field of immunology. Provided are broadly neutralizing antibodies against SARS-COV-2 variants, compositions and methods of prevention and treatment of SARS-COV-2 infection or transmission.
2.WO/2025/137632ANTIBODIES AGAINST HENIPAVIRUSES
WO 26.06.2025
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/US2024/061561 Applicant MAPP BIOPHARMACEUTICAL, INC. Inventor WEST, Brandyn
Provided herein are Henipavirus antibodies. These Henipavirus antibodies bind to the Henipavirus F glycoprotein and have neutralizing activity against different Henipavirus species and strains. These antibodies are used in methods of inducing an immune response and methods of inhibiting Henipavirus infection. Additionally provided are methods of treating an infectious disease using such antibodies.
3.20250206808Antibodies Against Henipaviruses
US 26.06.2025
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No 18991145 Applicant Mapp Biopharmaceutical, Inc. Inventor Brandyn WEST

Provided herein are Henipavirus antibodies. These Henipavirus antibodies bind to the Henipavirus F glycoprotein and have neutralizing activity against different Henipavirus species and strains. These antibodies are used in methods of inducing an immune response and methods of inhibiting Henipavirus infection. Additionally provided are methods of treating an infectious disease using such antibodies.

4.WO/2025/132544ANTIBODIES THAT BLOCK HIV1 CAPSID ENTRY INTO AN FG PHASE, TARGETING TO AND PASSAGE THROUGH NUCLEAR PORE COMPLEXES
WO 26.06.2025
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/EP2024/087049 Applicant MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. Inventor GÖRLICH, Dirk
The present invention pertains to the fields of antibody technology, biochemistry, medicine, pharmacology, infection biology, and anti-viral therapy. More specifically, it discloses antibodies, particularly single-domain antibodies, e.g., VHH antibodies that bind an assembled HIV-1 capsid such that the capsid is prevented from entering the permeability barrier of nuclear pore complexes, also called the FG phase. Through the effects of these antibodies, HIV-1 is effectively prevented from entering the cell's nucleus and thus blocked in its life cycle.
5.WO/2025/137284BROADLY NEUTRALIZING ANTIBODIES AGAINST SARS-COV-2 AND SARS-COV VARIANTS
WO 26.06.2025
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/US2024/061040 Applicant THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Inventor WANG, Lingshu
Disclosed are monoclonal antibodies, antigen binding fragments, and multi-specific antibodies that specifically bind a coronavirus spike protein, such as SARS-CoV-2. Also disclosed is the use of these antibodies and multi-specific antibodies for inhibiting a coronavirus infection, such as a SARS-CoV-2 infection. In addition, disclosed are methods for detecting a coronavirus, such as SARS-CoV-2, in a biological sample, using the disclosed antibodies and multi-specific antibodies.
6.WO/2025/135582ANTI-SFTS VIRUS ANTIBODY AND USE THEREOF
WO 26.06.2025
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/KR2024/019252 Applicant SCRIPPS KOREA ANTIBODY INSTITUTE Inventor SONG, Yong Bhum
The present invention relates to: an anti-SFTS virus antibody or an antigen-binding fragment thereof; a nucleic acid encoding same; a vector comprising the nucleic acid; a cell transformed with the vector; a method for preparing the antibody or the antigen-binding fragment thereof; a composition for preventing or treating SFTS virus infection, comprising same; and a composition for diagnosing same.
7.20250205355METHODS AND SYSTEMS FOR APPLICATIONS INVOLVING ANTIGEN-PRESENTING CELLS
US 26.06.2025
Int.Class A61K 47/68
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
Appl.No 18848612 Applicant Viska Bio, Inc. Inventor Eric T. Fossel

The present disclosure generally relates to systems and methods for treating and/or reversing a disease or condition such as aging, nonalcoholic steatohepatitis (NASH), neurodegenerative disease such as Alzheimer's and Parkinson's, obesity pulmonary fibrosis, congestive heart failure, or cancer using immunogenic cell death, e.g., lysosome-induced immunogenic cell death. In certain embodiments, the application is directed towards compositions that comprise an antibody and an enzyme capable of producing reactive oxygen species. In some cases, the lysosome of cells associated with the disease or condition may be targeted by the composition for induced cell death.

8.12338452Compositions for regulating production of an antibody like protein and ribonucleic acid
US 24.06.2025
Int.Class C12N 15/86
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
86Viral vectors
Appl.No 18945053 Applicant Wyvern Pharmaceuticals Inc. Inventor Bradley G. Thompson

Some embodiments of the present disclosure relate to one or more compositions for regulating the production of an antibody-like protein (ALP) and ribonucleic acid (RNA). In particular, the present disclosure relates to compositions for regulating the gene expression and, therefore, the production, of an ALP and an interfering RNA (iRNA), which may suppress viral infections. In some embodiments of the present disclosure, the target viral infection is a respiratory syncytial virus (RSV) infection.

9.822682Respiratory syncytial virus mRNA vaccine, and preparation method therefor and use thereof
NZ 24.06.2025
Int.Class C07K 14/005
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
Appl.No 822682 Applicant Hangzhou Tianlong Pharmaceutical Co., Ltd. Inventor Gengshen SONG
10.20250197481Antigen Binding Polypeptides, Antigen Binding Polypeptide Complexes and Methods of Use Thereof in HIV
US 19.06.2025
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No 18696493 Applicant ModeX Therapeutics, Inc. Inventor Ronnie Rong WEI

Disclosed are antigen binding polypeptides and antigen binding polypeptide complexes (e.g., antibodies and antigen binding fragments thereof) that bind to HIV proteins and have certain structural features. Also disclosed are polynucleotides and vectors encoding such polypeptides and polypeptide complexes; host cells; chimeric antigen receptors (CARs); immune cells; pharmaceutical compositions and kits containing such polypeptides and polypeptide complexes; and methods of using such polypeptides and polypeptide complexes in HIV.